Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
BMJ Open ; 6(5): e010765, 2016 05 04.
Artículo en Inglés | MEDLINE | ID: mdl-27147385

RESUMEN

OBJECTIVES: To investigate whether screening for malnutrition using the validated malnutrition universal screening tool (MUST) identifies specific characteristics of patients at risk, in patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). DESIGN: Cross-sectional study. SETTING: University Hospitals Coventry & Warwickshire NHS Trust; European Neuroendocrine Tumour Society Centre of Excellence. PARTICIPANTS: Patients with confirmed GEP-NET (n=161) of varying primary tumour sites, functioning status, grading, staging and treatment modalities. MAIN OUTCOME MEASURE: To identify disease and treatment-related characteristics of patients with GEP-NET who score using MUST, and should be directed to detailed nutritional assessment. RESULTS: MUST score was positive (≥1) in 14% of outpatients with GEP-NET. MUST-positive patients had lower faecal elastase concentrations compared to MUST-negative patients (244±37 vs 383±20 µg/g stool; p=0.018), and were more likely to be on treatment with long-acting somatostatin analogues (65 vs 38%, p=0.021). MUST-positive patients were also more likely to have rectal or unknown primary NET, whereas, frequencies of other GEP-NET including pancreatic NET were comparable between MUST-positive and MUST-negative patients. CONCLUSIONS: Given the frequency of patients identified at malnutrition risk using MUST in our relatively large and diverse GEP-NET cohort and the clinical implications of detecting malnutrition early, we recommend routine use of malnutrition screening in all patients with GEP-NET, and particularly in patients who are treated with long-acting somatostatin analogues.


Asunto(s)
Antineoplásicos/efectos adversos , Neoplasias Gastrointestinales/tratamiento farmacológico , Hormonas/efectos adversos , Desnutrición/inducido químicamente , Tumores Neuroendocrinos/tratamiento farmacológico , Neoplasias Pancreáticas/tratamiento farmacológico , Somatostatina/efectos adversos , Antineoplásicos/uso terapéutico , Biomarcadores/metabolismo , Estudios Transversales , Inglaterra/epidemiología , Femenino , Neoplasias Gastrointestinales/complicaciones , Neoplasias Gastrointestinales/metabolismo , Hormonas/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/complicaciones , Tumores Neuroendocrinos/metabolismo , Neoplasias Pancreáticas/complicaciones , Neoplasias Pancreáticas/metabolismo , Guías de Práctica Clínica como Asunto , Somatostatina/análogos & derivados , Somatostatina/uso terapéutico , Resultado del Tratamiento
2.
BMJ Case Rep ; 20112011 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-22678732

RESUMEN

An 18-year-old man presented with a 2 day history of breathlessness and left-sided chest pain, with no preceding trauma. He had no medical history of note, and had never smoked. He was in hypovolaemic shock, with Hb of 8.1 g/dl, and received fluid resuscitation. Chest x-ray (CXR) revealed left-sided hydropneumothorax, with the effusion of blood-consistency on CT thorax. Tube thoracostomy drained 1.7 litres of blood immediately. He remained haemodynamically stable after 4 units of blood transfusion on the first day with post-transfusion Hb 11 g/dl. Following cardiothoracic surgeon advice, tube was removed on day 5 draining total of 3.5 litres, with good response clinically and radiologically. Patient was well when followed up at 1 week after hospital discharge, with no recurrence and complete re-expansion of left lung on CXR.


Asunto(s)
Hemoneumotórax/diagnóstico por imagen , Hemoneumotórax/cirugía , Adolescente , Dolor en el Pecho/etiología , Drenaje , Disnea/etiología , Hemoneumotórax/complicaciones , Humanos , Masculino , Choque/etiología , Choque/terapia , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...